SCHEMBL12901718

SCHEMBL12901718

O=C(NCCNCc1cc[nH]c1)c1sccc1Nc1ccnc2[nH]ccc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NEK1 Q96PY6 1/20 0.36
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
AKT1 P31749 1/20 0.34
ROCK2 O75116 3/20 0.33
ROCK1 Q13464 3/20 0.33
CIT O14578 1/20 0.33
PRKD3 O94806 1/20 0.33
MAP4K4 O95819 1/20 0.33
PRKCB P05771 1/20 0.33
PRKCA P17252 1/20 0.33
PRKACA P17612 1/20 0.33
CSNK2A2 P19784 1/20 0.33
MARK3 P27448 1/20 0.33
BMPR1A P36894 1/20 0.33
CSNK1A1 P48729 1/20 0.33
CLK1 P49759 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12901738 0.89 KDR (0.40) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12900662 0.89 CTDSP1 (0.40) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12900661 0.87 AKT1 (0.41) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12900383 0.87 KDM4E (0.40) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12900705 0.87 ALDH1A1 (0.38) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12901028 0.87 NEK1 (0.36) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12901726 0.86 CCNK (0.37) NEK1JAK2JAK1TYK2MARK3
SCHEMBL12900689 0.86 NEK1 (0.36) NEK1JAK2JAK1TYK2AKT1
SCHEMBL12900387 0.86 CIT (0.39) JAK2JAK1TYK2AKT1ROCK2
SCHEMBL12900386 0.85 SCN3A (0.40) NEK1JAK2JAK1TYK2AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462141-B1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2017-09-27 EP disclosed
US-9023847-B2 Azaheterocyclic compounds MERCK PATENT GMBH (DE) 2015-05-05 US disclosed
US-20120277228-A1 Novel Azaheterocyclic Compounds MERCK PATENT GMBH (DE) 2012-11-01 US disclosed
WO-2011017009-A1 NOVEL AZAHETEROCYCLIC COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277228-A1 Novel Azaheterocyclic Compounds PCNA, MCL1, MYC NEK1 708/4885JAK2 633/4885JAK1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.